Development of Polymer and Surfactant Based Naringenin Nanosuspension for Improvement of Stability, Antioxidant, and Antitumour Activity

Table 1

Optimization parameters of NAR nanosuspensions stabilized by different concentrations of SDS and HPMC.

Samples	Particle size (nm) (mean ± SD)	PDI (mean ± SD)	Zp (mV) (mean ± SD)
SDS conc. (% w/v)
F1 (0.1)	1251 ± 14.9	0.52 ± 0.04	−25.9 ± 1.7
F2 (0.5)	674 ± 6.9	0.44 ± 0.02	−34.7 ± 1.9
F3 (1)	460 ± 7.3	0.33 ± 0.03	−40.6 ± 2.2
HPMC conc. (% w/v)
F4 (0.1)	1421 ± 13.6	0.58 ± 0.05	−5.8 ± 0.4
F5 (0.5)	760 ± 12.3	0.45 ± 0.03	−7.1 ± 0.8
F6 (1)	372 ± 3.50	0.32 ± 0.04	−8.8 ± 0.5

Drug : stabilizer (2 : 1) ratio; 15 homogenization cycles and pressure 1500 bar were fixed.